The gain- and loss-of-function studies revealed the oncogenic role of DLX6-AS1 in bladder cancer cells, and DLX6-AS1 also promoted EMT and enhanced Wnt/β-catenin signaling in bladder cancer cells. The gene discussed is DLX6; the disease is urinary bladder cancer.